WO2022110651A1 - Mir-30a-5p et son utilisation pour favoriser la régénération nerveuse et réparer une lésion nerveuse périphérique - Google Patents

Mir-30a-5p et son utilisation pour favoriser la régénération nerveuse et réparer une lésion nerveuse périphérique Download PDF

Info

Publication number
WO2022110651A1
WO2022110651A1 PCT/CN2021/092308 CN2021092308W WO2022110651A1 WO 2022110651 A1 WO2022110651 A1 WO 2022110651A1 CN 2021092308 W CN2021092308 W CN 2021092308W WO 2022110651 A1 WO2022110651 A1 WO 2022110651A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
cells
drg
drg neuron
add
Prior art date
Application number
PCT/CN2021/092308
Other languages
English (en)
Chinese (zh)
Inventor
丁斐
周松林
施海燕
从猛
沈宓
张琦
Original Assignee
南通大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南通大学 filed Critical 南通大学
Priority to AU2021307014A priority Critical patent/AU2021307014B2/en
Publication of WO2022110651A1 publication Critical patent/WO2022110651A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • the invention belongs to the technical field of biomedicine, in particular to a miR-30a-5p and its application in promoting nerve regeneration and repairing peripheral nerve damage.
  • peripheral nerve injury is a common clinical problem, which causes a great burden to the society and family.
  • Peripheral nerves can regenerate spontaneously after injury, but due to the limited regeneration rate, it is ultimately difficult to restore function. Therefore, fully exploring the cellular and molecular mechanisms of peripheral nerve injury regeneration will help to promote peripheral nerve function repair and provide a theoretical basis for clinical treatment.
  • microRNA is an endogenous non-coding small RNA with a length of about 21-23 nucleotides. Its main role is to inhibit the translation of target genes or Direct degradation of target genes. In the peripheral nervous system, miRNA can not only inhibit the apoptosis of neurons and promote the regeneration of neuronal axons, but also participate in the regulation of the proliferation and migration of glial cells. Studies have found that DRG neuron axon growth is helpful for the repair of peripheral nerve damage. Therefore, it is necessary to provide a new target that promotes the growth of DRG neuron axons and is helpful for the treatment of nerve injury.
  • the technical problem to be solved by the present invention is to provide a miR-30a-5p and its application in promoting nerve regeneration and repairing peripheral nerve damage.
  • Overexpression of miR-30a-5p in vitro can target Nrp1 and significantly promote the DRG neuron axis
  • the growth and regeneration of neurites provide a new target for the repair of peripheral nerve injury.
  • the embodiments of the present invention provide a miR-30a-5p, which is a molecular target for peripheral nerve damage repair.
  • the invention also provides a use of miR-30a-5p for preparing a drug for promoting nerve regeneration and repairing nerve damage.
  • the nerve injury is a peripheral nervous system sciatic nerve injury.
  • the present invention also provides an application of miR-30a-5p in promoting DRG neuron axon regeneration and peripheral nerve damage repair, including the following verification steps:
  • step S1 the specific steps of step S1 are:
  • DRG neurons were obtained from the red skin of 1d SD rats, and the dorsal root ganglia were taken out and placed in dissection solution HA, digested with 3mg/ml collagenase, 37°C, 30min;
  • miR-30a-5p mimics and negative control were mixed with transfection reagent, added to the neuron cells cultured in step S1.1, and replaced with neuron medium after 8 hours of culture;
  • step S2 are:
  • DRG neurons were obtained from the red skin of 1d SD rats, and the dorsal root ganglia were taken out and placed in dissection solution HA, digested with 3mg/ml collagenase, 37°C, 30min;
  • S2.1.4 Resuspend the cells in DMEM containing 5% FBS, pass through a 200-mesh sieve, and seed them into a microfluidic chamber coated with polylysine. After culturing for 4 hours, replace them with 2% B-27, Neurobasal medium with 2 mM glutamine and 10 ng/ml NGF, 10 mM cytarabine for depletion of non-neuronal cells;
  • the miR-30a-5p mimics and negative control were mixed with transfection reagent and added to the cultured neurons, and the culture medium was replaced after 8 hours of culture;
  • step S3 are:
  • DRG neurons were obtained from the red skin of SD rats on 1d. The dorsal root ganglia were taken out and placed in dissection solution HA, digested with an appropriate amount of 3mg/ml collagenase, 37°C, 30min;
  • the miR-30a-5p mimics and negative control were mixed with transfection reagent and added to the cultured neurons, and the culture medium was replaced after 8 hours of culture;
  • Stage 2 95°C for 10s, 60°C for 30s, 72°C for 10s;
  • Stage 3 95°C for 15s, 60°C for 1min, 95°C for 15s;
  • S3.4.1 Collect DRG neuron cells cultured for 3 days in vitro, rinse once with PBS, add cell lysate containing 1% protease inhibitor, lyse on ice for 5-10 min, until the cells are completely lysed; centrifuge at 4°C, 13000rpm, 10min, collect supernatant;
  • the present invention uses miR-30a-5p as a molecular intervention target, and overexpresses miR-30a-5p to promote the growth and regeneration of DRG neuron axons.
  • the present invention utilizes microfluidics to transfect DRG neurons in vitro with miR-30a-5p mimic, which can significantly promote the growth and regeneration of primary cultured DRG neuron axons.
  • the miR-30a-5p provided by the present invention can participate in the repair of peripheral nerve injury by regulating the growth of DRG neuron axons, which is helpful to better understand the important role of miRNA in the process of nerve injury repair, and is helpful for nerve injury after nerve injury. Therapies offer new targets.
  • Fig. 1 is a schematic diagram showing that in vitro overexpression of miR-30a-5p can significantly promote the growth of DRG neuron axons in Example 1 of the present invention
  • Figure 2 is a schematic diagram showing that in vitro overexpression of miR-30a-5p can significantly promote the regeneration of DRG neurons axons after injury in Example 2 of the present invention
  • Figure 3 is a schematic diagram showing that in vitro overexpression of miR-30a-5p can significantly inhibit the mRNA and protein expression of NRP1 in DRG neurons in Example 3 of the present invention.
  • the invention provides a miR-30a-5p, which is used as a molecular target for peripheral nerve injury repair, regulates DRG neurons in the process of peripheral nerve injury repair, and targets Nrp1 to significantly promote the growth and regeneration of DRG neuron axons.
  • miR-30a-5p is used to prepare drugs for promoting nerve regeneration and repairing nerve injury, wherein the nerve injury is the injury of the sciatic nerve in the peripheral nervous system.
  • the present invention also provides an application of miR-30a-5p in promoting DRG neuron axon regeneration and peripheral nerve damage repair, including the following verification steps:
  • Example 1 Cultivate primary DRG neuron cells, and observe in vitro overexpression of miR-30a-5p to promote DRG neuron axon growth. The specific steps are:
  • DRG neurons were obtained from the red skin of 1d SD rats, and the dorsal root ganglia were taken out and placed in dissection solution HA, digested with an appropriate amount of 3mg/ml collagenase, 37°C, 30min;
  • 1.1.4 Resuspend the cells in DMEM containing 5% FBS, pass through a 200-mesh sieve, and seed them into a microfluidic chamber coated with polylysine. After culturing for 4 h, replace the cells with 2% B-27, Neurobasal medium with 2 mM glutamine and 10 ng/ml NGF, 10 mM cytarabine was used to remove non-neuronal cells.
  • RNAiMAX Reagent was mixed with miR-30a-5p mimics and negative control (Guangzhou Ribo Bio Co., Ltd., the final concentration was 100 nM) and added to the neuron cells cultured in step S1.1. After 8 hours of culture, the medium was replaced with neuron medium.
  • Fig. 1A is Mimic Negative control (Mimic-NC, negative control) or miR-30a-5p mimics were transfected into DRG neurons cultured in microfluidics in vitro, and the cells were immunohistochemically stained 72 h later.
  • Figure 1B shows the average of at least 15 longest axons in DRG neurons transfected with Mimic-NC and miR-30a-5p mimics in vitro. *P ⁇ 0.05, ***P ⁇ 0.001.
  • Example 2 Cultivate primary DRG neuron cells and observe in vitro overexpression of miR-30a-5p to promote DRG neuron axon regeneration. The specific steps are as follows:
  • DRG neurons were obtained from the red skin of 1d SD rats. The dorsal root ganglia were taken out and placed in dissection solution HA, digested with an appropriate amount of 3mg/ml collagenase, 37°C, 30min;
  • RNAiMAX Reagent was mixed with miR-30a-5p mimics and negative control (Guangzhou Ribo Bio Co., Ltd., the final concentration was 100 nM) and added to the cultured neurons. After 8 h of culture, the culture medium was replaced with neuron medium.
  • Fig. 2A is Mimic Negative control (Mimic-NC, negative control) or miR-30a-5p mimics were transfected into DRG neurons cultured in microfluidics in vitro, and the growing axons were removed by negative pressure suction after 3 days.
  • Immunohistochemical staining of cells after 24h. The red light is Tuj1/Cy3, and then converted into grayscale image by Photoshop, Bar 100 ⁇ m.
  • Figure 2B shows the average of at least 15 longest axons in DRG neurons transfected with Mimic-NC and miR-30a-5p mimics in vitro. *P ⁇ 0.05, ***P ⁇ 0.001.
  • Example 3 Extracting primary DRG neuron cells to observe the inhibition of NRP1 mRNA and protein expression by overexpression of miR-30a-5p in vitro. The specific steps are as follows:
  • DRG neurons were obtained from the red skin of 1d SD rats, and the dorsal root ganglia were taken out and placed in dissection solution HA, digested with an appropriate amount of 3 mg/ml collagenase, 37 °C, 30 min;
  • RNAiMAX Reagent was mixed with miR-30a-5p mimics and negative control (Guangzhou Ribo Bio Co., Ltd., the final concentration was 100 nM) and added to the cultured neurons. After 8 h of culture, the culture medium was replaced with neuron medium.
  • Stage 2 (Cycle: 40): 95°C for 10s, 60°C for 30s, 72°C for 10s;
  • Stage 3 95°C for 15s, 60°C for 1min, 95°C for 15s;
  • Figure 3A The qRT-PCR results are shown in Figure 3A, which showed that overexpression of miR-30a-5p could significantly inhibit the mRNA level of NRP1 in DRG neurons compared with Mimic Negative control group.
  • Figure 3A shows DRG neurons cultured in vitro transfected with Mimic Negative control (Mimic-NC, negative control) or miR-30a-5p mimics, respectively, and the expression of NRP1 mRNA was detected by qRT-PCR after 72 h, and the internal reference was GAPDH. ***P ⁇ 0.001.
  • Figure 3B shows DRG neurons cultured in vitro transfected with Mimic Negative control (Mimic-NC, negative control) or miR-30a-5p mimics, respectively. The expression of NRP1 protein was detected by Western blot after 72 h, and the internal control was ⁇ -actin. **P ⁇ 0.01.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un miR-30a-5p et son utilisation pour favoriser la régénération nerveuse et réparer une lésion nerveuse périphérique. Le miR-30a-5p est une cible moléculaire pour réparer une lésion nerveuse périphérique, et est utilisé pour préparer un médicament pour favoriser la régénération nerveuse et réparer une lésion nerveuse. L'utilisation de celui-ci dans la promotion de la régénération axonale des neurones du ganglion spinal (DRG) et la réparation d'une lésion nerveuse périphérique comprend les étapes de vérification suivantes : S1, la culture de cellules neuronales du DRG primaires, et l'observation de la manière dont la surexpression in vitro du miR-30a-5p favorise la croissance axonale de neurone du DRG ; S2, la culture de cellules neuronales du DRG primaires, et l'observation de la manière dont la surexpression in vitro du miR-30a-5p favorise la régénération axonale de neurone du DRG ; S3, l'extraction de cellules neuronales du DRG primaires, et l'observation de la manière dont la surexpression in vitro du miR-30a-5p inhibe l'expression de l'ARNm et de la protéine NRP1. En utilisant le miR-30a-5p en tant que cible d'intervention moléculaire et surexprimant le miR-30a-5p, la croissance et la régénération des axones des neurones du DRG sont favorisées. Par la culture de neurones du DRG in vitro à l'aide de la microfluidique, et la transfection d'un mimétique de miR-30a-5p, la croissance et la régénération des axones des neurones du DRG primaires cultivés peuvent être sensiblement favorisées.
PCT/CN2021/092308 2020-11-24 2021-05-08 Mir-30a-5p et son utilisation pour favoriser la régénération nerveuse et réparer une lésion nerveuse périphérique WO2022110651A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021307014A AU2021307014B2 (en) 2020-11-24 2021-05-08 miR-30a-5p and application thereof in promoting nerve regeneration and repairing peripheral nerve injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011328557.X 2020-11-24
CN202011328557.XA CN112301033B (zh) 2020-11-24 2020-11-24 miR-30a-5p及其在促进神经再生和修复周围神经损伤方面的应用

Publications (1)

Publication Number Publication Date
WO2022110651A1 true WO2022110651A1 (fr) 2022-06-02

Family

ID=74335701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/092308 WO2022110651A1 (fr) 2020-11-24 2021-05-08 Mir-30a-5p et son utilisation pour favoriser la régénération nerveuse et réparer une lésion nerveuse périphérique

Country Status (3)

Country Link
CN (1) CN112301033B (fr)
AU (1) AU2021307014B2 (fr)
WO (1) WO2022110651A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112301033B (zh) * 2020-11-24 2021-11-19 南通大学 miR-30a-5p及其在促进神经再生和修复周围神经损伤方面的应用
CN114085833A (zh) * 2021-11-11 2022-02-25 南通大学 一种miR-25-3p、应用及其应用方法
WO2023238948A1 (fr) * 2022-06-09 2023-12-14 国立大学法人九州大学 Nouveau promoteur de neurogenèse cérébrale contenant un miarn

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128245A1 (fr) * 2005-06-03 2006-12-07 Southern Adelaide Health Service-Flinders Medical Centre Ciblage de cellules presentant un microarn d'expression modifiee
CN101386848A (zh) * 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
CN111514159A (zh) * 2020-06-02 2020-08-11 南通大学 miR-20a在促进神经再生和修复神经损伤方面的应用
WO2020168111A1 (fr) * 2019-02-15 2020-08-20 Exhaura, Ltd. Inhibiteurs de kinase à double glissière à leucine pour thérapie génique
CN112301033A (zh) * 2020-11-24 2021-02-02 南通大学 miR-30a-5p及其在促进神经再生和修复周围神经损伤方面的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105274055A (zh) * 2015-06-19 2016-01-27 南通大学 神经元原代培养的纯化方法
CN106913876B (zh) * 2017-02-24 2020-01-21 南方医科大学 miRNA-30a-5p在帕金森病检测、治疗、预后靶点的应用
CN111518884B (zh) * 2020-04-08 2022-02-18 中国医学科学院医药生物技术研究所 miRNA30簇作为阿尔茨海默病诊断标志物的应用
CN111643681A (zh) * 2020-06-18 2020-09-11 南通大学 Nr4a3在促进神经再生和修复神经损伤方面的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128245A1 (fr) * 2005-06-03 2006-12-07 Southern Adelaide Health Service-Flinders Medical Centre Ciblage de cellules presentant un microarn d'expression modifiee
CN101386848A (zh) * 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
WO2020168111A1 (fr) * 2019-02-15 2020-08-20 Exhaura, Ltd. Inhibiteurs de kinase à double glissière à leucine pour thérapie génique
CN111514159A (zh) * 2020-06-02 2020-08-11 南通大学 miR-20a在促进神经再生和修复神经损伤方面的应用
CN112301033A (zh) * 2020-11-24 2021-02-02 南通大学 miR-30a-5p及其在促进神经再生和修复周围神经损伤方面的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
XIAODONG FU, YI SHEN, WEILI WANG, XIAOMIAO LI: "MiR-30a-5p ameliorates spinal cord injury-induced inflammatory responses and oxidative stress by targeting Neurod 1 through MAPK/ERK signalling", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, WILEY-BLACKWELL PUBLISHING ASIA, AU, vol. 45, no. 1, 1 January 2018 (2018-01-01), AU , pages 68 - 74, XP055629100, ISSN: 0305-1870, DOI: 10.1111/1440-1681.12856 *
YANG MENGCHEN, WANG XIAOXUE, FAN YUESHAN, CHEN YAQING, SUN DONGDONG, XU XIN, WANG JIANHAO, GU GANG, PENG RUILONG, SHEN TIANYU, LIU: "Semaphorin 3A Contributes to Secondary Blood–Brain Barrier Damage After Traumatic Brain Injury", FRONTIERS IN CELLULAR NEUROSCIENCE, vol. 13, no. 117, 1 March 2019 (2019-03-01), pages 1 - 15, XP055934784, DOI: 10.3389/fncel.2019.00117 *
ZHU SHIPING, ZHOU ZHIGANG, LI ZHIZHONG, SHAO JIANLI, JIAO GENLONG, HUANG YU′EN, LIN YONGXIN: "Suppression of LINC00707 alleviates lipopolysaccharide-induced inflammation and apoptosis in PC-12 cells by regulated miR-30a-5p/Neurod 1", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY, JP, vol. 83, no. 11, 2 November 2019 (2019-11-02), JP , pages 2049 - 2056, XP055934780, ISSN: 0916-8451, DOI: 10.1080/09168451.2019.1637245 *

Also Published As

Publication number Publication date
CN112301033A (zh) 2021-02-02
CN112301033B (zh) 2021-11-19
AU2021307014B2 (en) 2022-07-28
AU2021307014A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
WO2022110651A1 (fr) Mir-30a-5p et son utilisation pour favoriser la régénération nerveuse et réparer une lésion nerveuse périphérique
Yoo et al. Nanogrooved substrate promotes direct lineage reprogramming of fibroblasts to functional induced dopaminergic neurons
Chong et al. Cellular demise and inflammatory microglial activation during β-amyloid toxicity are governed by Wnt1 and canonical signaling pathways
US20220403390A1 (en) Methods and compositions for reprogramming cells
EP3119879B1 (fr) Procédé pour induire la différenciation de cholangiocytes humains
Chen et al. mi R‐27 impairs the adipogenic lineage commitment via targeting lysyl oxidase
Ebrahimi-Barough et al. Derivation of pre-oligodendrocytes from human endometrial stromal cells by using overexpression of microRNA 338
Parreno et al. Tropomyosin 3.1 association with actin stress fibers is required for lens epithelial to mesenchymal transition
US20190010455A1 (en) Isolation And Use Of Pluripotent Stem Cell Population From Adult Neural Crest-Derived Tissues
Yuan et al. Dopaminergic precursors differentiated from human blood-derived induced neural stem cells improve symptoms of a mouse Parkinson's disease model
Li et al. Long-term corneal recovery by simultaneous delivery of hPSC-derived corneal endothelial precursors and nicotinamide
Tsao et al. Myostatin genetic inactivation inhibits myogenesis by muscle-derived stem cells in vitro but not when implanted in the mdx mouse muscle
Inada et al. Alkaline phosphatase and OCT‐3/4 as useful markers for predicting susceptibility of human deciduous teeth‐derived dental pulp cells to reprogramming factor‐induced iPS cells
Faroni et al. Expression of functional γ-aminobutyric acid type A receptors in Schwann-like adult stem cells
Yamashita et al. Culture substrate-associated YAP inactivation underlies chondrogenic differentiation of human induced pluripotent stem cells
García-García et al. Intermediate progenitors are increased by lengthening of the cell cycle through calcium signaling and p53 expression in human neural progenitors
Xu et al. Abnormal mitochondria in Down syndrome iPSC-derived GABAergic interneurons and organoids
Lee et al. Neural differentiation of bone marrow-derived mesenchymal stem cells: applicability for inner ear therapy
Jia et al. Transcription factor Tbx5 promotes cardiomyogenic differentiation of cardiac fibroblasts treated with 5‐azacytidine
Cao et al. MicroRNA-194 regulates the development and differentiation of sensory patches and statoacoustic ganglion of inner ear by Fgf4
Han et al. The miR‐3940‐5p inhibits cell proliferation of gingival mesenchymal stem cells
CN108048551B (zh) miR-139-3p及其拮抗剂在诊断和治疗骨骼系统疾病中的应用
Pesirikan et al. Characterization of schwann cells in self-assembled sheets from thermoresponsive substrates
CN105688227B (zh) miR-127在制备治疗肌肉疾病的药物中的用途
Askar et al. The Etv1/Er81 transcription factor coordinates myelination-related genes to regulate Schwann cell differentiation and myelination

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2021307014

Country of ref document: AU

Date of ref document: 20210508

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21896166

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21896166

Country of ref document: EP

Kind code of ref document: A1